Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression

Sun, Duxin; Xie, Xiao‐Bi; Zhang, Xiyuan; Wang, Zilai; Sait, Sameer Farouk; Iyer, Swathi V.; Chen, Yu-Jung; Brown, Rebecca M.; Laks, Dan R.; Chipman, Mollie E.; Shern, Jack F.; Parada, Luis F.

doi:10.1016/j.stem.2021.04.029

Cited by 29 publications

(33 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 e and f). These markers are associated with neuronal cytoskeleton formation [ [25] , [26] , [27] ], which was also confirmed by the immunocytochemical staining results ( Fig. 2 a).…”

Section: Resultssupporting

confidence: 71%

Electrical charge on ferroelectric nanocomposite membranes enhances SHED neural differentiation

Heng

Bai

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

“…2 e and f). These markers are associated with neuronal cytoskeleton formation [ [25] , [26] , [27] ], which was also confirmed by the immunocytochemical staining results ( Fig. 2 a).…”

Section: Resultssupporting

confidence: 71%

Electrical charge on ferroelectric nanocomposite membranes enhances SHED neural differentiation

Heng

Bai

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

“…[ 2 ] Endogenous methods, including luciferase‐based bioluminescence and fluorescent protein tagging, provide long‐term imaging through the continuous expression of encoded genes. [ 3 ] In addition to variable gene transfection efficiency, transgenesis methods suffer from unanticipated effects on normal cell functions, and are generally not compatible with use in humans. [ 4 ] Exogenous fluorescent probes, on the other hand, are simpler to administer and can be easily tailored for emission in the second near‐infrared window (NIR‐II, 1000−1700 nm), so as to reduce tissue scattering and absorption and allow direct labeling of deep tissues.…”

Section: Introductionmentioning

confidence: 99%

Conjugated Oligoelectrolytes for Long‐Term Tumor Tracking with Incremental NIR‐II Emission

Zhou

Zhu

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

The design and synthesis of the near‐infrared (NIR)‐II emissive conjugated oligoelectrolyte COE‐BBT are reported. COE‐BBT has a solubility in aqueous media greater than 50 mg mL−1, low toxicity, and a propensity to intercalate lipid bilayers, wherein it exhibits a higher emission quantum yield relative to aqueous media. Addition of COE‐BBT to cells provides two emission channels, at ≈500 and ≈1020 nm, depending on the excitation wavelength, which facilitates in vitro confocal microscopy and in vivo animal imaging. The NIR‐II emission of COE‐BBT is used to track intracranial and subcutaneous tumor progression in mice. Of relevance is that the total NIR‐II intensity increases over time. This phenomenon is attributed to a progressive attenuation of a COE‐BBT self‐quenching effect within the cells due to the expected dye dilution per cell as the tumor proliferates.

show abstract

“…Interestingly, the magenta module is strongly enriched in a series of terms describing development regulation of the peripheral nervous system and interactions between neurons and Schwann cells. Specifically, in magenta, a subset of neural crest progenitor markers, such as NES, SOX10, ERBB3, and NGFR, were reported as highly expressed markers of Schwann cell progenitors and the signatures of stem-like tumor cells in NF1 tumors [ 4 , 38 ]. Genes in different preserved modules are summarized in Supplementary Table S3 .…”

Section: Resultsmentioning

confidence: 99%

Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas

et al. 2022

Self Cite

View full text Add to dashboard Cite

Neurofibromatosis Type 1 (NF1) is one of the most common genetic tumor predisposition syndromes, affecting up to 1 in 2500 individuals. Up to half of patients with NF1 develop benign nerve sheath tumors called plexiform neurofibromas (PNs), characterized by biallelic NF1 loss. PNs can grow to immense sizes, cause extensive morbidity, and harbor a 15% lifetime risk of malignant transformation. Increasingly, molecular sequencing and drug screening data from various preclinical murine and human PN cell lines, murine models, and human PN tissues are available to help identify salient treatments for PNs. Despite this, Selumetinib, a MEK inhibitor, is the only currently FDA-approved pharmacotherapy for symptomatic and inoperable PNs in pediatric NF1 patients. The discovery of alternative and additional treatments has been hampered by the rarity of the disease, which makes prioritizing drugs to be tested in future clinical trials immensely important. Here, we propose a gene regulatory network-based integrated analysis to mine high-throughput cell line-based drug data combined with transcriptomes from resected human PN tumors. Conserved network modules were characterized and served as drug fingerprints reflecting the biological connections among drug effects and the inherent properties of PN cell lines and tissue. Drug candidates were ranked, and the therapeutic potential of drug combinations was evaluated via computational predication. Auspicious therapeutic agents and drug combinations were proposed for further investigation in preclinical and clinical trials.

show abstract

Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression

Cited by 29 publications

References 65 publications

Electrical charge on ferroelectric nanocomposite membranes enhances SHED neural differentiation

Electrical charge on ferroelectric nanocomposite membranes enhances SHED neural differentiation

Conjugated Oligoelectrolytes for Long‐Term Tumor Tracking with Incremental NIR‐II Emission

Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas

Contact Info

Product

Resources

About